Herpes Zoster Market Trends

Growth Drivers

• Increasing population of immunity weakness: The impact of deadly diseases on immunocompromised patients was highlighted during the pandemic strike. The results of the WHO ISARIC CCP-UK prospective cohort study revealed in January 2023, that the mortality rate in hospital admission accounted to be higher for immunocompromised patients. The study further mentioned the probability of death in such cases was 88% for men and 83% for women aged 50 to 69 years. It showcased the need for precautions to save people from potential viral infections such as shingles. This further propels demand in the market.
• Advancements in healthcare: The growing adoption of innovative solutions has stimulated acceptance in the herpes zoster market. Improved diagnosis, vaccination, and drugs are being developed for better patient outcomes. This brings versatility in novel treatment options, driving growth in this sector. It is further inspiring leaders to engage their assets in the form of financial support and clinical expertise in more R&D projects. For instance, in February 2022, Moderna, Inc. unveiled three new development programs to expand its pipeline of mRNA vaccines for herpes simplex virus (HSV) and varicella-zoster virus (VSV).

Challenges

• Expensive treatment and medication: Newly introduced medical solutions in the herpes zoster market may become unaffordable for patients. Significant expenses on long-term treatment may also prevent low-income populations from adopting new treatment methods. In addition, limitations in health insurance coverage for such diseases may restrict access to prevention and treatment. This makes it difficult for the suppliers or service providers to widespread adequate treatment programs for shingles, hindering growth in this sector.
• Limited awareness and acceptance among consumers: Despite government promotions and proven efficacy, patients often hesitate to adopt vaccinations or new medications from the herpes zoster market. Misconceptions about the disease or treatment safety may also become a hurdle for authorities to reduce shingles incidences. This can dilute their interest in optimum implementation in healthcare facilities and investment. Moreover, the lack of knowledge in consumers may result in delayed diagnosis and treatment, limiting the proper effectiveness of these solutions.